Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy

Journal of Neuroinflammation

Volumn 10, Issue , 2013, Pages

  Yilmaz, Aylin ^a   Yiannoutsos, Constantin T ^b   Fuchs, Dietmar ^c   Price, Richard W ^d   Crozier, Kathryn ^d   Hagberg, Lars ^a   Spudich, Serena ^e   Gisslén, Magnus ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b INDIANA UNIVERSITY   (United States)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Cerebrospinal fluid; HIV 1 RNA; Neopterin

Indexed keywords

ANTIRETROVIRUS AGENT; NEOPTERIN; VIRUS RNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BLOOD ANALYSIS; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84877299797     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-10-62     Document Type: Article

References (29)

1. Fuchs D, Spira TJ, Hausen A, Reibnegger G, Werner ER, Felmayer GW, Wachter H. Neopterin as a predictive marker for disease progression in human immunodeficiency virus type 1 infection. Clin Chem 1989, 35:1746-1749.
2. Furukawa Y, Nishi K, Kondo T, Tanabe K, Mizuno Y. Significance of CSF total neopterin and biopterin in inflammatory neurological diseases. J Neurol Sci 1992, 111:65-72. 10.1016/0022-510X(92)90113-Y, 1402999.
3. Fredrikson S, Link H, Eneroth P. CSF neopterin as marker of disease activity in multiple sclerosis. Acta Neurol Scand 1987, 75:352-355.
4. Hagberg L, Dotevall L, Norkrans G, Larsson M, Wachter H, Fuchs D. Cerebrospinal fluid neopterin concentrations in central nervous system infection. J Infect Dis 1993, 168:1285-1288. 10.1093/infdis/168.5.1285, 8228365.
5. Wirleitner B, Reider D, Ebner S, Böck G, Widner B, Jaeger M, Schennach H, Fuchs D. Monocyte-derived dendritic cells release neopterin. J Leukoc Biol 2002, 72:1148-1153.
6. Cano OD, Neurauter G, Fuchs D, Shearer GM, Boasso A. Differential effect of type I and type II interferons on neopterin production and amino acid metabolism in human astrocyte-derived cells. Neurosci Lett 2008, 13:22-25.
7. Griffin DE, McArthur JC, Cornblath DR. Neopterin and interferon-gamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease. Neurology 1991, 41:69-74.
8. Hagberg L, Cinque P, Gisslen M, Brew BJ, Spudich S, Bestetti A, Price RW, Fuchs D. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther 2010, 7:15. 10.1186/1742-6405-7-15, 2890504, 20525234.
9. Brew BJ, Pemberton L, Cunningham P, Law MG. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 1997, 175:963-966. 10.1086/514001, 9086160.
10. Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslén M. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS 2002, 16:2145-2149. 10.1097/00002030-200211080-00006, 12409735.
11. Edén A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis 2007, 196:1779-1783. 10.1086/523648, 18190258.
12. Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis 2006, 194:1686-1696. 10.1086/508750, 17109340.
13. Werner ER, Bichler A, Daxenbichler G, Fuchs D, Fuith LC, Hausen A, Hetzel H, Reibnegger G, Wachter H. Determination of neopterin in serum and urine. Clin Chem 1987, 33:62-66.
14. Mayersbach P, Augustin R, Schennach H, Schonitzer D, Werner ER, Wachter H, Reibnegger G. Commercial enzyme-linked immunosorbent assay for neopterin detection in blood donations compared with RIA and HPLC. Clin Chem 1994, 40:265-266.
15. Hagberg L, Andersson L, Abdulle S, Gisslén M. Clinical application of cerebrospinal fluid neopterin concentrations in HIV infection. Pteridines 2004, 15:102-106.
16. Lindstrom ML, Bates DM. Nonlinear mixed effects models for repeated measures data. Biometrics 1990, 46:673-687. 10.2307/2532087, 2242409.
17. Pinheiro J, Bates D. Approximations to the log-likelihood function in the nonlinear mixed-effects model. J Computational and Graphical Statistics 1995, 4:12-35.
18. Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med 2010, 18:45-55.
19. Bogner JR, Matuschke A, Heinrich B, Eberle E, Goebel FD. Serum neopterin levels as predictor of AIDS. Klin Wochenschr 1988, 66:1015-1018. 10.1007/BF01733445, 2467041.
20. Gisslén M, Fuchs D, Svennerholm B, Hagberg L. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr 1999, 21:271-276. 10.1097/00126334-199908010-00003, 10428104.
21. Bogner JR, Junge-Hulsing B, Kronawitter U, Sadri I, Matuschke A, Goebel FD. Expansion of neopterin and beta 2-microglobulin in cerebrospinal fluid reaches maximum levels early and late in the course of human immunodeficiency virus infection. Clin Investig 1992, 70:665-669.
22. Fuchs D, Chiodi F, Albert J, Asjö B, Hagberg L, Hausen A, Norkrans G, Reibnegger G, Werner ER, Wachter H. Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1. AIDS 1989, 3:285-288. 10.1097/00002030-198905000-00006, 2504232.
23. Brew BJ, Bhalla RB, Paul M, Gallardo H, McArthur JC, Schwartz MK, Price RW. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol 1990, 28:556-560. 10.1002/ana.410280413, 2252366.
24. Gisslén M, Svennerholm B, Fuchs D, Hagberg L. Neurological efficacy of stavudine, zidovudine, and lamivudine. Lancet 1998, 352:402-403.
25. Mellgren A, Antinori A, Cinque P, Price RW, Eggers C, Hagberg L, Gisslén M. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther 2005, 10:701-707.
26. Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 47:168-173. 10.1097/QAI.0b013e31815ace97, 2628632, 17971711.
27. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005, 5:69-81. 10.1038/nri1527, 15630430.
28. Aurelius E, Forsgren M, Skoldenberg B, Strannegard O. Persistent intrathecal immune activation in patients with herpes simplex encephalitis. J Infect Dis 1993, 168:1248-1252. 10.1093/infdis/168.5.1248, 8228358.
29. Schnell G, Spudich S, Harrington P, Price RW, Swanstrom R. Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog 2009, 5:e1000395. 10.1371/journal.ppat.1000395, 2668697, 19390619.